Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Implant Sciences Corp.

This article was originally published in The Gray Sheet

Executive Summary

Receives license to manufacture and distribute the I-Plant Iodine-125 brachytherapy seeds from the Radiation Control Program of the Commonwealth of Massachusetts' Department of Public Health, administrator for the Nuclear Regulatory Commission's oversight of radioactive source manufacture, the company announces Jan. 12. Implant Sciences received FDA 510(k) clearance for the seeds in May for the treatment of prostate cancer
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT012828

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel